Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Alberto Garcia Hernandez"'
Autor:
Kim M. Gooding, Chrysta Lienczewski, Massimo Papale, Niina Koivuviita, Marlena Maziarz, Anna-Maria Dutius Andersson, Kanishka Sharma, Paola Pontrelli, Alberto Garcia Hernandez, Julie Bailey, Kay Tobin, Virva Saunavaara, Anna Zetterqvist, David Shelley, Irvin Teh, Claire Ball, Sapna Puppala, Mark Ibberson, Anil Karihaloo, Kaj Metsärinne, Rosamonde E. Banks, Peter S. Gilmour, Michael Mansfield, Mark Gilchrist, Dick de Zeeuw, Hiddo J. L. Heerspink, Pirjo Nuutila, Matthias Kretzler, Matthew Welberry Smith, Loreto Gesualdo, Dennis Andress, Nicolas Grenier, Angela C. Shore, Maria F. Gomez, Steven Sourbron, for the BEAt-DKD consortium
Publikováno v:
BMC Nephrology, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background Diabetic kidney disease (DKD) remains one of the leading causes of premature death in diabetes. DKD is classified on albuminuria and reduced kidney function (estimated glomerular filtration rate (eGFR)) but these have modest value
Externí odkaz:
https://doaj.org/article/e94cbf7fb6ec48ce9d18b5b1e307048f
Autor:
Quan Dong Nguyen, Yasir J. Sepah, Brian Berger, David Brown, Diana V. Do, Alberto Garcia-Hernandez, Sunil Patel, Firas M. Rahhal, Yevgeniy Shildkrot, Ronny W. Renfurm, the VIDI Research Group
Publikováno v:
International Journal of Retina and Vitreous, Vol 5, Iss 1, Pp 1-14 (2019)
Abstract Background ASP8232 is a potent and specific small molecule vascular adhesion protein-1 (VAP-1) inhibitor. This study evaluated the effect of ASP8232 on excess retinal thickness when given alone or in combination with ranibizumab in patients
Externí odkaz:
https://doaj.org/article/230bedcb74a6439cb544798aa8be2ffd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Pharmaceutical Statistics, 19(6), 909-927. John Wiley & Sons Ltd.
In pre-marketing stages of drug development, trialists focus on drug efficacy rather than effectiveness, and observations collected after study drug discontinuation are excluded from the analysis, following the so-called “de jure” estimand. In th
Autor:
Tobias E Larsson, Hartmut Onkels, Sven Hoefman, Nelleke Snelder, Kirsten R. Bergmann, Alberto Garcia-Hernandez
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
ASP8232 is a novel inhibitor of vascular adhesion protein-1 that was under evaluation for reducing residual albuminuria in patients with diabetic kidney disease. To characterize the pharmacokinetics (PK) of ASP8232 and its effect on vascular adhesion
Autor:
Nelleke Snelder, Tobias E Larsson, Sven Hoefman, Kirsten R. Bergmann, Alberto Garcia-Hernandez, Martijn van Noort, Hartmut Onkels
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
The vascular adhesion protein-1 (VAP-1) inhibitor ASP8232 reduces albuminuria in patients with type 2 diabetes and chronic kidney disease. A mechanism-based model was developed to quantify the effects of ASP8232 on renal markers from a placebo-contro
Publikováno v:
Endocrine. 75(1)
Autor:
Alberto Garcia Hernandez, Pablo Alvarez, Fina Parramon, Alfredo Muñoz, Nuria Estanyol, Carmen Requena Hernández, Marc Vives, Berta Pardina
Publikováno v:
International Journal of Nephrology and Renovascular Disease. 12:153-166
Acute kidney injury (AKI) is a major medical problem that is of particular concern after cardiac surgery. Perioperative AKI is independently associated with an increase in short-term morbidity, costs of treatment, and long-term mortality. In this rev
Publikováno v:
The American Journal of Case Reports
Case series Patients: Male, 49-year-old • Male, 61-year-old • Female, 64-year-old Final Diagnosis: COVID-19 Symptoms: Respiratory distress Medication: — Clinical Procedure: — Specialty: Infectious Diseases • Pulmonology Objective: Unusual s
Autor:
Dick de Zeeuw, M.W. Mansfield, Matthew Wellberry-Smith, Nicolas Grenier, Anna V. Zetterqvist, Anna-Maria Dutius Andersson, Kim M. Gooding, Loreto Gesualdo, Massimo Papale, Irvin Teh, Hiddo J.L. Heerspink, Chrysta Lienczewski, Peter S. Gilmour, Sapna Puppala, Pirjo Nuutila, Paola Pontrelli, Mark Gilchrist, Claire Ball, Rosamonde E. Banks, David Shelley, Anil Karihaloo, Marlena Maziarz, Alberto Garcia Hernandez, iBEAt investigators, Kay Tobin, Steven Sourbron, Niina Koivuviita, Angela C. Shore, Mark Ibberson, Matthias Kretzler, Dennis L. Andress, Kanishka Sharma, Julie Bailey, Maria F. Gomez, Kaj Metsärinne, Virva Saunavaara
Publikováno v:
BMC Nephrology
Bmc nephrology, 21(1):242. BMC
BMC Nephrology, Vol 21, Iss 1, Pp 1-11 (2020)
Bmc nephrology, 21(1):242. BMC
BMC Nephrology, Vol 21, Iss 1, Pp 1-11 (2020)
Background Diabetic kidney disease (DKD) remains one of the leading causes of premature death in diabetes. DKD is classified on albuminuria and reduced kidney function (estimated glomerular filtration rate (eGFR)) but these have modest value for pred